Gengraf Capsules and Glecaprevir and pibrentasvir

In the database of official manuals used in the service creation an interaction registered by statistical results of studies was found, which can either lead to negative consequences for the patient health or strengthen a mutual positive effect. A doctor should be consulted to address the issue of joint drug administration.

CycloSPORINE may significantly increase the blood levels of glecaprevir. This may increase the risk of liver problems that can occasionally occur during treatment with glecaprevir. Talk to your doctor if you have any questions or concerns. Your doctor may be able to prescribe alternatives that do not interact. You should seek immediate medical attention if you have fever, chills, joint pain or swelling, unusual bleeding or bruising, skin rash, itching, loss of appetite, fatigue, nausea, vomiting, abdominal pain, dark urine, pale stools, and/or yellowing of the skin or eyes, as these may be signs and symptoms of liver damage. It is important to tell your doctor about all other medications you use, including vitamins and herbs. Do not stop using any medications without first talking to your doctor.

GENERALLY AVOID: Coadministration with cyclosporine may significantly increase the plasma concentrations of glecaprevir. The proposed mechanism is inhibition of organic anion transporting polypeptide (OATP) 1B1-mediated hepatic uptake of glecaprevir by cyclosporine. Inhibition of P-glycoprotein (P-gp)- and breast cancer resistance protein (BCRP)-mediated intestinal transport and CYP450 3A4-mediated metabolism of glecaprevir may also contribute. When glecaprevir-pibrentasvir 300 mg-120 mg once daily was administered with a single 100 mg dose of cyclosporine to 12 study subjects, glecaprevir peak plasma concentration (Cmax), systemic exposure (AUC) and trough plasma concentration (Cmin) increased by just 30% to 40%. However, when a single 300 mg-120 mg dose of glecaprevir-pibrentasvir was administered with a single 400 mg dose of cyclosporine, glecaprevir Cmax and AUC increased by approximately 4.5- and 5.1-fold, respectively, and pibrentasvir AUC also nearly doubled. High plasma levels of glecaprevir may increase the risk of adverse effects such as alanine aminotransferase (ALT) and bilirubin elevations.

MANAGEMENT: Glecaprevir-pibrentasvir is not recommended for use in patients requiring stable cyclosporine dosages greater than 100 mg/day.

Gengraf Capsules

Generic Name: cyclosporine

Brand name: Gengraf, Neoral, Sandimmune, Sandimmune

Synonyms: Gengraf (Capsules, Modified), Gengraf

What is Gengraf Capsules?

Glecaprevir and pibrentasvir

Generic Name: glecaprevir / pibrentasvir

Brand name: Mavyret

Synonyms: Glecaprevir and Pibrentasvir

What is Glecaprevir and pibrentasvir?